nfr-logonfr-logo
PROSJEKTBANKEN
Switch to English
Se statistikken
Se prosjektene

0 antall prosjekter

Dato fra ny til gammel

PES-HORISONT-EU-PES Horisont Europa

LTX-109. Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential

Airborne viruses can be quite dangerous, especially for groups of risk (e.g. immunocompromised patients), as they can replicate and migrate from the upper (nose/nasopharynx) into lower respiratory tract (lungs) and lead to severe conditions such as pneumonia. Indeed, the nose is the main site for...

Tildelt: kr 0,30 mill.

Prosjektperiode: 2023-2023

Sted: Troms - Romsa - Tromssa

PES-HORISONT-EU-PES Horisont Europa

LTX-109 as a therapeutic and prophylactic agent for upper respiratory tract infections

The SARS-CoV-2 pandemic is expected to become endemic in the coming years with occasional flare-ups. In particular, the continual emergence of new coronavirus variants, some of which may be resistant to current vaccines, pose a risk. It is therefore expected that the need for new safe and effecti...

Tildelt: kr 99 999

Prosjektperiode: 2022-2022

Sted: Troms - Romsa - Tromssa

PES-HORISONT-EU-PES Horisont Europa

Clinical testing program for use of LTX-109 as treatment against COVID-19 infection.

In 2020, Pharma Holdings has conducted an in vitro study to determine the effect of LTX-109 on three enveloped viruses, one being the SARS-CoV-2 virus. The results are compelling and confirm that LTX-109 exerts a virucidal effect against the SARS-CoV-2 virus. Pharma Holdings believes that the in ...

Tildelt: kr 0,40 mill.

Prosjektperiode: 2021-2021

Sted: Troms - Romsa - Tromssa

PES2020-Prosj.etabl.støtte H2020

Development of the first of its kind medication for combined treatment of viral and bacterial conjunctivitis.

Pharma Holdings (https://www.pharmaholdings.no) is developing eyedrops for the treatment of conjunctivitis caused by both bacteria and viruses based on LTX-109. LTX-109 is a novel antimicrobial synthetic peptide with a fast-acting membrane lysing mode of action. It is a short cationic synthetic p...

Tildelt: kr 99 999

Prosjektperiode: 2020-2021

Sted: Troms - Romsa - Tromssa

BIA-Brukerstyrt innovasjonsarena

Nasal Decolonization to prevent post-surgical infections.

Mennesket er det naturlige reservoaret for bakterien S. aureus, og 20-50% av friske voksne er kolonisert i nesen med bakterien. Nasal S. aureus er den viktigste årsaken til S. aureus-infeksjoner. USA, EU og Verdens Helseorganisasjon anbefaler alle dekolonisering av S. aureus for å forhindre posto...

Tildelt: kr 9,6 mill.

Prosjektperiode: 2020-2022

Sted: Troms - Romsa - Tromssa

1